{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T19:56:43Z","timestamp":1784318203321,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Anding Hospital Institutional Research Fund","award":["ADYKHT2023004"],"award-info":[{"award-number":["ADYKHT2023004"]}]},{"name":"Natural Science Foundation of Tianjin Municipal Science and Technology Bureau","award":["22JCZDJC00110"],"award-info":[{"award-number":["22JCZDJC00110"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to investigate the effects of atypical antipsychotic drugs (AAPDs) on changes in body composition and fat distribution characteristics in patients with first-episode schizophrenia (FSCZ) and chronic schizophrenia (CSCZ), as well as to predict their temporal trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 70 inpatients (51 FSCZ, 19 CSCZ) admitted to Tianjin Anding Hospital from January 2023 to June 2024 were enrolled. Body composition indicators, including weight (W), Body Mass Index (BMI), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), abdominal skinfold thickness (ASF), body fat (BF), body fat percentage (BFP), and visceral fat area (VFA) were measured at baseline and every 4 weeks over a 12-week period. A linear mixed-effects model (LMM) was used to analyze dynamic changes, and independent t-tests were used to compare baseline differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In FSCZ patients, W, BMI, WC, ASF, BF, and BFP increased significantly over time (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The olanzapine group (Group A) showed the steepest slopes for W (1.85\u00a0kg\/4 weeks), BMI (0.70\u00a0kg\/m\u00b2\/4 weeks), and WC (3.07\u00a0cm\/4 weeks) (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01), indicating central obesity. In CSCZ patients, no significant changes in body composition were observed (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009\u2265\u20090.08), but baseline values of W, BMI, and WC were higher than those of FSCZ patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). A LMM predicted that FSCZ patients would reach CSCZ levels in W, BMI, and WC in approximately 64, 42, and 28 weeks, respectively, with other indices reaching similar levels within 22.2\u201367.7 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this preliminary longitudinal study, AAPDs - particularly olanzapine - were associated with rapid and significant increases in central obesity among FSCZ patients. whereas CSCZ patients exhibited metabolic stability over the short observation period. These findings suggest that both disease stage and treatment phase play critical roles in shaping body fat distribution trajectories. The early phase of antipsychotic treatment may represent a vulnerable period for targeted metabolic monitoring and timely intervention to prevent long-term cardiometabolic risks. While these results provide preliminary evidence for stage-specific metabolic patterns, confirmation in larger, randomized, and longer-term studies is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-07540-6","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:04:43Z","timestamp":1764583483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal effects of atypical antipsychotic drugs on body composition in first-episode and chronic schizophrenia patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Qi","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"7540_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.encep.2013.03.002","volume":"41","author":"MA Crocq","year":"2015","unstructured":"Crocq MA. A history of antipsychotic long-acting injections in the treatment of schizophrenia. Encephale. 2015;41(1):84\u201392. https:\/\/doi.org\/10.1016\/j.encep.2013.03.002.","journal-title":"Encephale"},{"key":"7540_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/NDT.S286024","volume":"17","author":"B Kearns","year":"2021","unstructured":"Kearns B, Cooper K, Cantrell A, Lewis R, Brennan A, Holmes E, et al. Schizophrenia treatment with second-generation antipsychotics: a multi-country comparison of the costs of cardiovascular and metabolic adverse events and weight gain. Neuropsychiatr Dis Treat. 2021;17:125\u201337. https:\/\/doi.org\/10.2147\/NDT.S286024.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"7540_CR3","doi-asserted-by":"publisher","first-page":"661174","DOI":"10.3389\/fpsyt.2021.661174","volume":"12","author":"EG Kornetova","year":"2021","unstructured":"Kornetova EG, Kornetov AN, Mednova IA, Gerasimova VI, Boiko AS, Dobrodeeva VS, et al. Comparative characteristics of the metabolic syndrome prevalence in patients with schizophrenia in three Western Siberia psychiatric hospitals. Front Psychiatry. 2021;12:661174. https:\/\/doi.org\/10.3389\/fpsyt.2021.661174.","journal-title":"Front Psychiatry"},{"issue":"7","key":"7540_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ijnp\/pyad025","volume":"26","author":"CU Correll","year":"2023","unstructured":"Correll CU, H\u00f8jlund M, Graham C, Belger M, Gopal S, Mathews M, et al. Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis. Int J Neuropsychopharmacol. 2023;26(7):451\u201364. https:\/\/doi.org\/10.1093\/ijnp\/pyad025.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"7540_CR5","doi-asserted-by":"publisher","first-page":"21m14110","DOI":"10.4088\/JCP.21m14110","volume":"83","author":"M Piras","year":"2022","unstructured":"Piras M, Dubath C, Gholam M, Giordano A, Conus P, Baumann P, et al. Daily dose effects of Risperidone on weight and other metabolic parameters: a prospective cohort study. J Clin Psychiatry. 2022;83(4):21m14110. https:\/\/doi.org\/10.4088\/JCP.21m14110.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"7540_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3892\/mmr.2025.13212","volume":"31","author":"A Manta","year":"2025","unstructured":"Manta A, Georganta A, Roumpou A, Koukoulis G, Kaprinis G, Papakosta VM, et al. Metabolic syndrome in patients with schizophrenia: underlying mechanisms and therapeutic approaches. Mol Med Rep. 2025;31(5):114. https:\/\/doi.org\/10.3892\/mmr.2025.13212.","journal-title":"Mol Med Rep"},{"issue":"2","key":"7540_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20957","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248\u201371. https:\/\/doi.org\/10.1002\/wps.20957.","journal-title":"World Psychiatry"},{"issue":"1","key":"7540_CR8","doi-asserted-by":"publisher","first-page":"7583","DOI":"10.1038\/s41598-021-87087-1","volume":"11","author":"M Srisurapanont","year":"2021","unstructured":"Srisurapanont M, Suttajit S, Likhitsathian S, Suttajit T, Maneeton B, Maneeton N. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine\/samidorphan and olanzapine. Sci Rep. 2021;11(1):7583. https:\/\/doi.org\/10.1038\/s41598-021-87087-1.","journal-title":"Sci Rep"},{"issue":"4","key":"7540_CR9","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3892\/etm.2019.7307","volume":"17","author":"E Hatziagelaki","year":"2019","unstructured":"Hatziagelaki E, Tsiavou A, Gerasimou C, Mastorakos G, Vitoratou D, Papageorgiou C. Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis. Exp Ther Med. 2019;17(4):3071\u20136. https:\/\/doi.org\/10.3892\/etm.2019.7307.","journal-title":"Exp Ther Med"},{"key":"7540_CR10","doi-asserted-by":"publisher","first-page":"711940","DOI":"10.3389\/fphar.2021.711940","volume":"12","author":"P Soria-Chacartegui","year":"2021","unstructured":"Soria-Chacartegui P, Villapalos-Garc\u00eda G, Zubiaur P, Abad-Santos F. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, Aripiprazole and Risperidone. Front Pharmacol. 2021;12:711940. https:\/\/doi.org\/10.3389\/fphar.2021.711940.","journal-title":"Front Pharmacol"},{"key":"7540_CR11","doi-asserted-by":"publisher","first-page":"103594","DOI":"10.1016\/j.ajp.2023.103594","volume":"84","author":"T Zhou","year":"2023","unstructured":"Zhou T, Pu C, Huang Z, Lin J, Xu Y, Yang Y, et al. Weight changes following treatment with aripiprazole, Risperidone and olanzapine: a 12-month study of first-episode schizophrenia patients in China. Asian J Psychiatr. 2023;84:103594. https:\/\/doi.org\/10.1016\/j.ajp.2023.103594.","journal-title":"Asian J Psychiatr"},{"issue":"1","key":"7540_CR12","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1192\/bjo.2022.568","volume":"9","author":"B Campforts","year":"2023","unstructured":"Campforts B, Drukker M, Crins J, Drukker T, Guloksuz S, van Os J. Association between antipsychotic medication and clinically relevant weight change: meta-analysis. BJPsych Open. 2023;9(1):e18. https:\/\/doi.org\/10.1192\/bjo.2022.568.","journal-title":"BJPsych Open"},{"key":"7540_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2022.01.021","volume":"244","author":"\u00c0G Segura","year":"2022","unstructured":"Segura \u00c0G, Mart\u00ednez-Pinte\u00f1o A, Gass\u00f3 P, Arranz MJ, Mas S, Lafuente A. Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first-episode psychosis cohort. Schizophr Res. 2022;244:101\u201310. https:\/\/doi.org\/10.1016\/j.schres.2022.01.021.","journal-title":"Schizophr Res"},{"key":"7540_CR14","doi-asserted-by":"publisher","first-page":"815456","DOI":"10.3389\/fnut.2021.815456","volume":"8","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee S, Skrede S, Milbank E, Skaaby T, Johansson H, Andreassen OA, et al. Understanding the effects of antipsychotics on appetite control. Front Nutr. 2022;8:815456. https:\/\/doi.org\/10.3389\/fnut.2021.815456.","journal-title":"Front Nutr"},{"key":"7540_CR15","doi-asserted-by":"publisher","first-page":"113101","DOI":"10.1016\/j.bbr.2020.113101","volume":"402","author":"TR Prestwood","year":"2021","unstructured":"Prestwood TR, Asgariroozbehani R, Wu S, Huber K, Karmacharya R, Nguyen TT, et al. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res. 2021;402:113101. https:\/\/doi.org\/10.1016\/j.bbr.2020.113101.","journal-title":"Behav Brain Res"},{"key":"7540_CR16","doi-asserted-by":"publisher","first-page":"105849","DOI":"10.1016\/j.jsbmb.2021.105849","volume":"209","author":"N Hetem\u00e4ki","year":"2021","unstructured":"Hetem\u00e4ki N, Mikkola TS, Tikkanen MJ, Wang F, T\u00f6rm\u00e4l\u00e4 R, Sepp\u00e4l\u00e4 J, et al. Adipose tissue Estrogen production and metabolism in premenopausal women. J Steroid Biochem Mol Biol. 2021;209:105849. https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105849.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"7540_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fpubh.2020.00180","volume":"8","author":"CR Stephens","year":"2020","unstructured":"Stephens CR, Easton JF, Robles-Cabrera A, Higgins M, Valdez G, Antu\u00f1a S, et al. The impact of education and age on metabolic disorders. Front Public Health. 2020;8:180. https:\/\/doi.org\/10.3389\/fpubh.2020.00180.","journal-title":"Front Public Health"},{"issue":"7","key":"7540_CR18","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/jcm14072402","volume":"14","author":"AA Obeidat","year":"2025","unstructured":"Obeidat AA, Ahmad MN, Ghabashi MA, Al-Mazidi Z, Al-Harbi T, Al-Qahtani A, et al. Developmental trends of metabolic syndrome in the past two decades: a narrative review. J Clin Med. 2025;14(7):2402. https:\/\/doi.org\/10.3390\/jcm14072402.","journal-title":"J Clin Med"},{"issue":"1","key":"7540_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230340","volume":"181","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Kwan ATH, Rosenblat JD, Mansur RB, Ho R, Gill H, et al. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry. 2024;181(1):26\u201338. https:\/\/doi.org\/10.1176\/appi.ajp.20230340.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"7540_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64\u201377. https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"7540_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ph14030238","volume":"14","author":"A Ventriglio","year":"2021","unstructured":"Ventriglio A, Baldessarini RJ, Vitrani G, Bonfitto I, Ricci F, Delvecchio G, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14(3):238. https:\/\/doi.org\/10.3390\/ph14030238.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7540_CR22","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva V. Antipsychotic-induced weight gain and metabolic dysfunction: a review of pathophysiology and management strategies. Psych Scene Hub. 2022. Available from: https:\/\/psychscenehub.com\/psychinsights"},{"issue":"6","key":"7540_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/acps.13638","volume":"149","author":"M Rogdaki","year":"2024","unstructured":"Rogdaki M, Fernandez-Egea E, Bullmore ET, Marques TR, Howes OD, Murray RM. Weight and metabolic changes in early psychosis\u2014association with daily quantification of medication exposure during the first hospitalization. Acta Psychiatr Scand. 2024;149(6):465\u201376. https:\/\/doi.org\/10.1111\/acps.13638.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"7540_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/schbul\/sbr148","volume":"39","author":"AJ Mitchell","year":"2013","unstructured":"Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306\u201318. https:\/\/doi.org\/10.1093\/schbul\/sbr148.","journal-title":"Schizophr Bull"},{"issue":"12","key":"7540_CR25","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1007\/s00213-021-05971-y","volume":"238","author":"X Lang","year":"2021","unstructured":"Lang X, Liu Q, Fang H, Jiang Y, Wang J, Li Z, et al. The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia. Psychopharmacology. 2021;238(12):3643\u201352. https:\/\/doi.org\/10.1007\/s00213-021-05971-y.","journal-title":"Psychopharmacology"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07540-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-07540-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-07540-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:04:45Z","timestamp":1764583485000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-07540-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7540"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-07540-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Tianjin Anding Hospital (Ethical Approval Number: 2022-10). All participants provided written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1138"}}